SPORE in Ovarian Cancer
SPORE in Ovarian Cancer
批准号:
10222600
负责人:
IE-MING SHIH
金额:
$230.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-18 至 2023-07-31
关键词:
AddressAdjuvant TherapyAffectBiostatistics CoreBloodCancer BiologyCancer EtiologyCancer PatientCarboplatinCarcinomaCarcinoma in SituCervicalCessation of lifeClinicalClinical DataCombined Modality TherapyComplexDNA DamageDataDetectionDeveloped CountriesDevelopmentDiagnosisDiseaseDisease remissionDrug resistanceEarly DiagnosisEarly treatmentEnsureFive-Year PlansFundingFutureGeneticGenomicsGoalsHistologicIncidenceInstitutionLaboratory ResearchLesionLibrariesLiquid substanceMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMeasurableMedicalMolecularMolecular GeneticsMonitorMorbidity - disease rateNew AgentsOperative Surgical ProceduresOutcomeOvarianOvarian CarcinomaPaclitaxelPathologicPathologyPathway interactionsPatient advocacyPatientsPennsylvaniaPerioperativePlatinumPreventionProgress Review GroupProgression-Free SurvivalsProteomicsRecurrent diseaseReproduction sporesResearchResearch Project GrantsResistanceResourcesRisk MarkerSYK geneScientistScreening for Ovarian CancerSerousSpecimenTechnologyTestingTimeLineTranslatingTranslational ResearchTranslationsTreatment outcomeTubeTumor BiologyTyrosine Kinase InhibitorUnited StatesUniversitiesUterine cavityWomanWorkanticancer researchantitumor effectbasebiobankbiomarker identificationcancer cellcancer therapycareerchemotherapyclinical applicationcollaborative environmentcombatcytotoxicdrug developmenteffective therapyhuman capitalimprovedinhibitor/antagonistinnovationmortalitymultimodalityneoplastic cellnovelnovel strategiesnovel therapeutic interventionpre-clinicalprogramssuccesstechnology developmenttumortumor DNAtumor heterogeneity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OVARIAN CANCER SPORE: SUMMARY
Ovarian cancer is one of the most aggressive cancers in women in the United States and a major cause of
cancer morbidity and mortality. This Johns Hopkins-University of Pennsylvania Ovarian Cancer SPORE
application focuses on reducing ovarian cancer incidence and mortality by translating new laboratory research
discoveries made in our institution into improvements in ovarian cancer detection and treatment. This highly
translational program contains four hypothesis-driven Research Projects, three Core Resources, the Career
Enhancement Program, and the Developmental Research Program. The objective of Project 1 is to determine
whether detection of tumor cells from liquid-based cervical fluid specimens, endometrial cavity brushing and/or
circulating tumor DNA (ctDNA) from blood can identify early and low-volume ovarian high-grade serous
carcinoma (HGSC), the most common type of ovarian carcinoma, or its precursor lesion, serous tubal
intraepithelial carcinoma. The goal of Project 2 and Project 3 is to provide critical preclinical and early clinical
data for developing more effective combined therapy to treat advanced ovarian HGSC, especially for recurrent
diseases. Specifically, Project 2 is to optimize synthetic lethality in high-grade ovarian serous ovarian cancer
by using ATR inhibitor and PARP inhibitor. Project 3 based on a recent discovery made by our team proposes
to apply BET inhibitors for overcoming platinum resistance. Project 4 aims to determine that inhibition of
Spleen Tyrosine Kinase (SYK) activity sensitizes ovarian cancer cells to the cytotoxic effect of paclitaxel, and
determine if SYK inhibitor represents a promising new agent to be combined with (weekly) paclitaxel for the
treatment of advanced ovarian cancer.
These Projects are supported by an Administrative Core, a Biorepository/Pathology Core, and a Biostatistics
Core. Finally, the Career Enhancement and Developmental Research Programs comprise pipelines of human
capital and innovative ideas, respectively, which will fuel future SPORE advances. This application is strongly
supported by institutional commitment to ensure its success.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach
-
批准号:10673186
-
项目类别:
-
资助金额:$92.31万
-
财政年份:2022
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:10626987
-
项目类别:
-
资助金额:$66.09万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:9979935
-
项目类别:
-
资助金额:$69.82万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:10381500
-
项目类别:
-
资助金额:$66.96万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Admin Core
-
批准号:10478839
-
项目类别:
-
资助金额:$15.7万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
-
批准号:10222607
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
SPORE in Ovarian Cancer
-
批准号:10478838
-
项目类别:
-
资助金额:$158.91万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
-
批准号:10478850
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
SPORE in Ovarian Cancer
-
批准号:9975108
-
项目类别:
-
资助金额:$197.7万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
Admin Core
-
批准号:10222601
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:10376915
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:9903253
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:8996905
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Tumor Suppressor Role of ARID1A
-
批准号:8400414
-
项目类别:
-
资助金额:$19.87万
-
财政年份:2011
-
负责人:IE-MING SHIH
-
依托单位:
Tumor Suppressor Role of ARID1A
-
批准号:8257679
-
项目类别:
-
资助金额:$17.62万
-
财政年份:2011
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:8009489
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:7582307
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:7471941
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:8209302
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:7760912
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
海外基金